Another Potential Neurodegenerative Disease Drug Fails in Clinical Trials

On the heels of the disappointing announcement that the Phase III ALS clinical trial of the antibiotic ceftriaxone has been stopped, a Phase III clinical trial of the potential Alzheimer’s disease therapeutic, bapineuzumab, has also been halted. Bapineuzumab is an antibody that targets the Abeta peptide and was being tested for the treatment of patients with mild to moderate Alzheimer’s disease. Although the results of the Phase II efficacy trial were promising, the Phase III study failed to show any effect on daily function or cognition in people with Alzheimer’s disease.

Click here to read more.

Share this: